Biomarker for PTSD Discovered
Researchers believe they have made a landmark discovery toward an objective diagnosis of post-traumatic stress disorder (PTSD).
University of Minnesota and Minneapolis VA Medical Center scientists studied a group of 74 United States veterans. They were able to objectively diagnose PTSD using magnetoencephalography (MEG), a non-invasive measurement of magnetic fields in the brain.
The outcome is meaningful because conventional brain scans such as an X-ray, CT, or MRI have been unsuccessful in identifying PTSD.
The ability to objectively diagnose PTSD is the first step towards helping those afflicted with this severe anxiety disorder. PTSD, like all mental disorders, is currently diagnosed through a symptom checklist that a mental health professional uses to make a reliable diagnosis.
PTSD often stems from war, but also can be a result of exposure to any psychologically traumatic event. The disorder can manifest itself in flashbacks, recurring nightmares, anger, or hypervigilance.
With more than 90 percent accuracy, researchers were able to differentiate PTSD patients from healthy control subjects (250 people with clean mental health) using the MEG. All behavior and cognition in the brain involves networks of nerves continuously interacting — these interactions occur on a millisecond by millisecond basis.
However, the study did not examine the use of MEG with people who have other mental health conditions. Without studying other mental health conditions as well, there’s no way to determine whether the researchers’ findings will hold up when differentiating PTSD from depression, anxiety or some other mental disorder.
The MEG has 248 sensors that record the interactions in the brain on a millisecond by millisecond basis, much faster than current methods of evaluation such as the functional magnetic resonance imaging (fMRI), which takes seconds to record.
The measurements recorded by the MEG represent the workings of tens of thousands of brain cells. This recording method allowed researchers to locate unique biomarkers in the brains of patients exhibiting PTSD.
The findings are published in the Journal of Neural Engineering and led by Apostolos Georgopoulos, M.D., Ph.D., and Brian Engdahl., Ph.D. – both members of the Brain Sciences Center at the Minneapolis VA Medical Center and University of Minnesota.
“These findings document robust differences in brain function between the PTSD and control groups that can be used for differential diagnosis and which possess the potential for assessing and monitoring disease progression and effects of therapy,” Georgopoulos claimed. A differential diagnosis, however, cannot be made based upon just this data alone.
Besides diagnosing those with PTSD, the researchers also are able to judge the severity of how much they are suffering, which means the MEG may be able to be used to gauge the how badly patients are impacted by other brain disorders.
This work, specifically on detecting post-traumatic stress disorder, follows success in detecting other brain diseases, such as Alzheimer’s and multiple sclerosis, using MEG, as reported in September 2007.
Source: University of Minnesota
Nauert PhD, R. (2018). Biomarker for PTSD Discovered. Psych Central. Retrieved on August 3, 2020, from https://psychcentral.com/news/2010/01/21/biomarker-for-ptsd-discovered/10878.html